Trials / Terminated
TerminatedNCT03448978
Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma
Phase I Safety and Feasibility Study of Autologous CD8+ T-cells Transiently Expressing a Chimeric Antigen Receptor Directed to B-Cell Maturation Antigen in Patients With Multiple Myeloma
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Cartesian Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This Phase I study will test the safety and anti-myeloma activity of ascending doses of Descartes-08 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in eligible patients with active multiple myeloma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Descartes-08 | autologous CD8+ T-cells transiently expressing an anti-BCMA chimeric antigen receptor |
| DRUG | Fludarabine | intravenous fludarabine |
| DRUG | Cyclophosphamide | intravenous cyclophosphamide |
Timeline
- Start date
- 2018-03-08
- Primary completion
- 2021-04-19
- Completion
- 2021-06-03
- First posted
- 2018-02-28
- Last updated
- 2024-07-01
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03448978. Inclusion in this directory is not an endorsement.